People

Karen Richards is an Avestria adviser specializing in diagnostic regulation, quality systems, clinical trials and compliance. Her published career includes in-vitro diagnostics and quality work at Precision for Medicine and regulatory submissions in multiple jurisdictions.

Margot Shapiro is an Avestria adviser with private-equity and venture experience. Her published background includes Goldman Sachs, the Wolverine Venture Fund, co-founding LMN Ventures with Linda Greub and Corinne Nevinny, and Spiral Sun Ventures. She studied at Stanford and Harvard Business School.

Andrew J. Perlman, published as Andy Perlman in Avestria’s adviser directory, is a physician-scientist with drug-development experience. His biography identifies co-founding work at AI drug-discovery company X-37 and Velocity Pharmaceutical Development, and earlier roles at Tularik, Genentech, Innate Immune and Affymax. He studied physics at MIT and medicine and science at NYU.

Corinne Nevinny co-founded Avestria with Linda Greub in 2019 and is listed in its current adviser directory. Her published career includes healthcare investment banking and executive finance and operations roles at Tularik and Edwards Lifesciences. She studied engineering at Stanford and business at Harvard.

Chimene Linette Liburd, listed in Avestria’s directory as Chimene Liburd, is a physician executive and adviser. Her published background includes primary care, clinical operations, Medicare and Medicaid health plans, and medical training at the University of Maryland.

Susan Knowles advises Avestria with genomic testing and life-science business experience. Her published career includes investment banking, Applied Biosystems, Illumina and genomics services at UCSF Health.

Jennifer Koski is an Avestria adviser whose published background includes finance research and teaching at the University of Washington’s Foster School of Business. She earned degrees at Brown, Harvard Business School and Stanford.

Mindy Goldman is an Avestria adviser with obstetrics and gynecology expertise. Her published biography describes UCSF clinical work addressing gynecologic health for breast-cancer survivors and women at high hereditary cancer risk.

Julia Helvey directs social media at Avestria. Her published biography describes biology training at Brigham Young University and experience in the University of Utah hospital’s labor and delivery unit.

Michelle Branch is a venture partner and legal counsel at Avestria. Her legal experience includes Wilson Sonsini, a boutique practice advising venture funds and startups, and teaching at New York University Law School. She holds degrees from Stanford and the University of California, Berkeley.

Lisa Gaudio directs marketing at Avestria. She has marketing experience across consumer-product categories, studied accounting at the University of Scranton and attended Harvard Business School. Her work communicates developments in women’s health and the firm’s portfolio.

Tracy Dooley is an Avestria partner trained in biomedical engineering at USC and medicine at Stanford. Her published experience includes healthcare M&A, strategy and global operations at Novartis Diagnostics, and digital-health advisory work.

Linda Greub co-founded Avestria and leads the firm as managing partner. Her published career spans healthcare investment research, equity management and corporate development at Applied Biosystems and other life-science companies. She studied at Yale and Harvard Business School and holds the CFA designation.

Thomas Bech Hansen is vice director of New Business and Technologies at FORCE Technology. The September11,2026 ministerial announcement appoints him to Innovation Fund Denmark’s board for July1,2027 through June30,2030, succeeding Mette Glavind. This future appointment is not represented as an October2026current directorship. The announcement also records his previous service on the Danish Council for Research and Innovation Policy.

Christian H. M. Ketels is named as a vice chair in Innovation Fund Denmark’s annual report signed March23,2026. He is absent from the institution’s current authoritative Danish board directory. This is a historical published governance affiliation, with no inferred exact departure date or current employee role.

Sine Reker Hadrup is a professor and section leader in DTU’s Department of Health Technology, where her research group studies T cells and cancer. Innovation Fund Denmark’s March2026annual report names her as a director. She is absent from the current authoritative Danish board roster, so the institution affiliation is retained as explicitly historical; the stale English directory is not evidence of continued membership.

Sonia Singh is Athensmed’s current Investment Manager. Her published biography describes business-development and venture-capital experience, responsibility across investment analysis and portfolio development, and work on governance and the measurement of social impact in healthcare companies. Additional credentials or earlier employers are not asserted where the firm does not publish them.

Kustaa Piha is Athensmed’s founder and CEO, a Finnish physician and healthcare entrepreneur with a2014 medical doctorate and master’s qualifications in political science and economics. He co-founded MedGroup in2007, developed multiple healthcare-service businesses and founded Lähilääkärit in2025. His current Athensmed biography emphasizes long-term ownership, health equality and research-based healthcare investment; the firm’s investments are not automatically attributed to him personally.

Peter Holme Jensen founded Aquaporin and previously served as its CEO. Aquaporin’s own2024director nomination records his service as Chief Innovation Officer from January2022 through January2024 and subsequent work as an entrepreneur and professional director. Innovation Fund Denmark’s current Danish directory includes him on the board and Programme Oversight committee; the translated English directory omits his board card.

Morten Novak Bro is CEO of maritime control-technology company EMRI, whose own corporate history says he took over the role in2023. Innovation Fund Denmark’s current Danish directory publishes him as a board member and member of the Programme Oversight committee. These institution governance roles do not imply personal subscription to its grants.

Mette Glavind is director of the Building and Construction division at the Danish Technological Institute. She is a current Innovation Fund Denmark board member and chairs its Programme Oversight committee. The September11,2026 official announcement extends her board appointment through June30,2027; Thomas Bech Hansen is scheduled to succeed her from July1,2027.

Jes Broeng is a serial technology entrepreneur, professor and director of DTU Entrepreneurship and DTU Skylab. He holds a DTU PhD and works across photonics, research commercialization, technology transfer, intellectual property and early-stage business development. His DTU profile identifies him as cofounder of Crystal Fibre, Norlase, Bifrost Communications, Aqubiq, OSAA Innovation and OptoCeutics. The September11,2026 ministerial announcement appoints him to Innovation Fund Denmark’s board through June30,2029.

Ingrid Sofie Harbo was appointed to Innovation Fund Denmark’s board in the September11,2026 ministerial announcement, for a term through June30,2029. She co-owns Harbo Enterprises ApS and holds a University of Copenhagen PhD in biostatistics. Her professional experience spans more than30years in life-sciences research and innovation, leadership and digital transformation, including assessment work for Innobooster and the Industrial Researcher programme.

Henrik Østergaard Breitenbauch is a published current board member of Innovation Fund Denmark. The Royal Danish Defence College appointed him dean from March1,2022. His earlier work included directing the Centre for Military Studies at the University of Copenhagen, strategic work for NATO and research in Danish defence and international affairs. He holds a political-science PhD from the University of Copenhagen.

Charlotte Rønhof is a published current board member of Innovation Fund Denmark. The current SEGES Innovation organization page separately identifies her as an external director and supplies her original portrait. These governance roles are distinct from employment on the public funding institution’s staff.

Philipp J. H. Schröder is an economics professor at Aarhus University and director of the FIND Research Centre. His research covers international trade, industrial economics and macroeconomics. Innovation Fund Denmark names him vice chair; the September11,2026 ministerial announcement renewed his appointment through June30,2029, superseding the directory’s older term-end label.

Anders Eldrup chairs Innovation Fund Denmark. He previously served as Permanent Secretary in Denmark’s Ministry of Finance and CEO of DONG Energy. His professional work spans public administration, corporate governance, innovation and the green transition. The institution records his board entry on March7,2022 and current term through June30,2027.

Reitze Douma is publicly listed as Inkef’s Chief Finance & Risk Officer. In a personal2023 announcement he described joining Inkef as Managing Partner after fifteen years at APG Asset Management. The dated appointment title is distinguished from the current manager directory’s finance-and-risk title.

Najma Labyad is publicly listed as Inkef’s Financial Director. The manager identifies her finance function and publishes an authentic name-bound portrait. A detailed current primary career biography and exact joining date are not published on its reviewed directory; no broader executive or investment remit is assumed.

Cher Shen Kiar is a Senior Associate at Inkef, supporting healthcare-investment diligence and portfolio management. His published investor-panel biography describes three years of biomedical R&D and early drug-discovery experience, with an MRes from King’s College London and a BSc from University College London.

Ryan Sarver is publicly listed as an Inkef Partner. His self-published career account describes joining Redpoint in2013 after work on Twitter’s developer platform and later transitioning from Redpoint. The current Inkef affiliation is independently published by the manager; no personal portfolio check is inferred from this role.

Thijs Cohen Tervaert is an Inkef Partner who joined the firm in2016, combining medical training with healthcare and technology investment experience. He graduated in medicine from Leiden University, previously worked at Boston Consulting Group and helped establish the Amsterdam Health and Technology Institute. His portfolio board experience includes Scenic Biotech, TargED, iOnctura, ViCentra and Castor.

Frank Lansink is listed as an Inkef Partner and is identified as General Partner in Quantum Motion’s September2026 investor interview. He describes Inkef’s long-term support for silicon-spin quantum computing, starting with its2020 SeriesA and continuing through subsequent rounds. The sourced professional role is distinct from unrelated similarly named businesses.

Corné Jansen joined Inkef in2015 and helped build its technology portfolio, including GitLab and Remote. Coalition Capital announced him as its General Partner inJune2024. Inkef’s current site still lists him as Partner and its2026 Quantum Motion investment post credits his continuing portfolio work; the profile preserves this published affiliation without guessing whether he remains a full-time Inkef employee.

Anthony Barry is published by Pfizer Ventures as Executive Director, WWBD / Partner. Anthony Barry, PhD, is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. In this role, Anthony is responsible for identifying, evaluating, making, and managing equity investments aligned with the future scientific and strategic directions of Pfizer. He manages Pfizer's venture investments in early-stage biotechnology and platform companies, with a particular focus on novel therapeutic modalities, advanced drug delivery systems, and digital health innovations that have the potential to shape the future of healthcare. Anthony brings over 20 years of distinguished experience at Pfizer, where he has successfully led platform technology groups and external R&D innovation initiatives. Prior to joining the Pfizer Ventures team, he served as the Emerging Science Lead for Biotherapeutics, Technologies and Digital, where he scouted and secured strategic external collaborations and early-stage licensing opportunities. Throughout his career, he has been a key driver in identifying and accelerating emerging science to deliver breakthroughs to patients, and has championed the integration of advanced technologies, including artificial intelligence and machine learning (AI/ML), within the therapeutic discovery and pharmaceutical formulation pipeline. Anthony received his Bachelor of Arts (BA) in Chemistry from Carleton College and earned his Doctor of Philosophy (PhD) in Pharmaceutics from the University of Utah.

Irena Melnikova is published by Pfizer Ventures as Executive Director, WWBD / Partner. Irena Melnikova, PhD, is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Irena is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. Currently, she has responsibilities for Pfizer’s investments in Artios Pharma, CellCentric, Crossbow Therapeutics, Enodia Therapeutics, Flare Therapeutics, Levicept, Oblenio Bio and Priovant. Irena also served as Director of Telavant Holdings until its acquisition by Roche for $7.1 billion. Irena is an accomplished biopharma and finance executive with over 20 years of experience in equity financings in both public and private markets, corporate strategy, business development, and operations. Prior to Pfizer Ventures, Irena served as the Chief Financial Officer at Umoja Biopharma where she was a senior member of the executive team responsible for all aspects of financial strategy and operations of the company. Prior to Umoja, Irena served as a Managing Director, Biopharma Investment Banking at Leerink Partners, where she provided critical advice to biopharma companies and their boards on equity financing strategies, completing over 80 transactions raising over $9 billion for clients. Earlier in her career, Irena held leadership positions at Sanofi and TVM Capital; the latter - a global life sciences venture capital firm. Irena brings a strong scientific background and proven capacity to work across a wide range of therapeutic areas and technology platforms. She earned a Ph.D. in Molecular Medicine/Molecular Biology from the University of Texas.

Michael C. Diem is published by Pfizer Ventures as Vice President, WWBD / Senior Managing Partner. Michael C. Diem, MD is the Senior Managing Partner of Pfizer Ventures and Vice President, Worldwide Business Development. Mike is a member of Pfizer’s WWBD Leadership Team where he is responsible for leading Pfizer Ventures and Global Search and Evaluation. Mike has spent the last two decades as an executive and investor in the pharmaceutical and biotech industries. Before joining Pfizer, Mike was the Chief Financial Officer and Chief Business Officer at Century Therapeutics. Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier, Mike was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca. At GlaxoSmithKline (GSK), he led business development for the company’s rare disease business unit and was also a partner in GSK’s corporate venture firm, SR One. He has served on numerous corporate boards and is currently a director at OTR Therapeutics, Vibrant Therapeutics and FoRx Therapeutics and a board observer at Cour Pharmaceuticals and Carrick Therapeutics. Dr. Diem obtained his MD from the Rutgers-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow.

Overland’s company channel announced his international-growth appointment in October2026. Earlier roles included defense sales at SIG SAUER and European and Asian business development at Oshkosh.

Published name: John Kim. Published company-directory affiliation (function not disclosed) at Overland AI. Existing unrelated same-name identities preserved.

Vibeke Schrøder is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Troels Jørgensen is published by Innovation Fund Denmark as Senior Relations Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Troels Brøns Kjems is published by Innovation Fund Denmark as Senior Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Thomas Nybo Riis is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Søren Asp Mikkelsen is published by Innovation Fund Denmark as VP - Chief Program Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Stine Bach Holm is published by Innovation Fund Denmark as Program Officer, International & Missions (parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Sophie Bogø Rahbek Dyrskjøt is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Simone Uhrenholt Kovacevic is published by Innovation Fund Denmark as Student Assistant, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Sheimaa Shahid is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Rikke Dyrberg Georgi is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Rebecca Stiig Vibæk is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Raphael Matias Christensen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Pia Westergaard is published by Innovation Fund Denmark as Service & Facility Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Patrick Lund-Sørensen is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikoline Yuyan Skov Sørensen is published by Innovation Fund Denmark as Student Assistant, Jura & Compliance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikolaj Pallesen is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nikolai Karl is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nadia Holdgaard Krog is published by Innovation Fund Denmark as Compliance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Nadia Aron is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Monica Milter Ehlers is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Miranda Elkjær-Christensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Michael Hougaard Sandgreen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Michael Friis Lindinger is published by Innovation Fund Denmark as VP - Chief Financial Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mette-Marie Nielsen is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mette Toft Bangsø is published by Innovation Fund Denmark as Executive Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Sunita Williams is listed by Vast as Astronaut. Retired NASA astronaut and U.S. Navy captain with extensive orbital mission, command and spacewalk experience.

Megan McArthur is listed by Vast as Astronaut. Former NASA astronaut with two space missions, including Hubble servicing and a SpaceX Dragon mission.

Garrett Reisman is listed by Vast as Astronaut. Former NASA astronaut with two ISS missions, former SpaceX space-operations director and USC astronautical-engineering professor.

Clay Mowry is listed by Vast as Advisor. Commercial space experience includes Voyager Space and Blue Origin sales leadership.

Peter Russell-Clarke is listed by Vast as Advisor. Industrial designer whose work includes Apple devices, facilities, materials and manufacturing processes.

Will Heltsley is listed by Vast as Advisor. Previously SpaceX vice president of propulsion, with work on Merlin and Raptor engines.

Alex Hudson is listed by Vast as Advisor. Engineering experience spans spacecraft, quantum computing and scientific instruments; formerly led SpaceX avionics.

Steve Isakowitz is listed by Vast as Advisor. Previously led The Aerospace Corporation and held senior positions at Virgin Galactic, NASA and the U.S. Department of Energy.

Kathy Lueders is listed by Vast as Advisor. Former NASA human-spaceflight leader and SpaceX Starbase general manager; published biography also lists the Texas Space Commission vice chair role.

Hans Koenigsmann is listed by Vast as Advisor. Former SpaceX vice president for mission assurance.

Benjamin Leeds is listed by Vast as Senior Director, Ground Software & Mission Systems. Part of the early Launcher team, responsible for ground software and ground-segment engineering.

Molly McCormick is listed by Vast as Principal Engineer. Spaceflight experience includes Crew Dragon certification, Cargo Dragon operations and lunar payload programmes at Honeybee Robotics.

Mark Groskreutz is listed by Vast as Vice President, Propulsion. Propulsion experience includes Honeywell, SpaceX Merlin and Raptor engines, and Ursa Major.

Sergei Tanygin is listed by Vast as Vice President, Flight Dynamics & GNC. Astrodynamics and guidance experience includes STK and SpaceX launch-vehicle and spacecraft programmes.

Randy Huang is listed by Vast as Vice President, Avionics. Previously an engineering executive at Pacific Defense and a space-systems engineering leader at Raytheon.

Marcos Simon is listed by Vast as Vice President, Flight Safety & Mission Assurance. Previously worked on human-spaceflight safety and mission assurance at SpaceX and Blue Origin.

Derek Hassmann is listed by Vast as Vice President, Mission Operations. Human-spaceflight operations experience includes NASA, Axiom Space, Collins Aerospace and Bigelow Aerospace.

Eric Massey is listed by Vast as Senior Vice President, Software and Avionics. Software engineering experience includes JPL, SpaceX, Google Search and the Netflix data platform.

Colin Smith is listed by Vast as Senior Vice President, Haven-1 Program. Former SpaceX engineer who worked on Dragon and launch vehicles; a founding Vast team member leading Haven-1 development.

Jim Martz is listed by Vast as Senior Vice President, Special Projects. Engineering experience includes SpaceX, NASA JPL, Muon Space and Zipline, including spacecraft power and avionics.

Jesse Leeds is listed by Vast as Vice President, Global Security and Intelligence. Previously led security and crisis management at Match Group and served in U.S. intelligence and law enforcement.

Tom Shelley is listed by Vast as Vice President, Crew Partnerships. Previously president of Space Adventures, with experience arranging and delivering private astronaut flights.

Richard Leshner is listed by Vast as Vice President, Policy and Government Relations. Space-policy experience includes NASA, the White House and Planet Labs.

Eva Behrend is listed by Vast as Vice President, Communications. Communications experience includes Uber, SpaceX and Chime and work in corporate and public policy communications.

Shane Cioni is listed by Vast as Vice President, Manufacturing. Manufacturing and integration experience includes SpaceX, Virgin Orbit and Relativity Space.

Nicole Jordan is listed by Vast as Vice President, Mission Management. Previously NASA operations manager for the Commercial Crew Program, with human-spaceflight mission and engineering experience.

Melanie Stricklan is listed by Vast as Senior Vice President, Special Programs. Co-founded Slingshot Aerospace and served in the U.S. Air Force before commercial space leadership roles.

JP Hemingway is listed by Vast as Senior Vice President, Satellite Business Development & Commercialization. Previously held commercial and leadership positions at SES Satellites, O3b Networks and Ciena.

Kyle Dedmon is listed by Vast as Senior Vice President, Operations. Previously helped develop SpaceX manufacturing facilities for Starlink and its launch and spacecraft programmes.

Naoko Yamazaki is listed by Vast as General Manager, Vast Japan GK; Astronaut. Former JAXA astronaut who flew to the International Space Station in 2010 and has Japanese space-policy experience.

David Goodwin is listed by Vast as General Counsel. Legal experience covers aerospace, manufacturing, government contracts, supply chains and investigations.

Lucie Ravelojaona is listed by Vast as Chief of Staff. Engineer with aviation experience at Airbus and responsibility for strategic initiatives.

Daniel DeMattia is listed by Vast as Chief Information Officer. Infrastructure and security experience includes SpaceX, Virgin Orbit and Reliable Robotics.

Hillary Coe is listed by Vast as Chief Design and Marketing Officer. Design experience includes SpaceX human spaceflight communications and work at Google, Apple and Starlink.

Giorgio Saccoccia is listed by Vast as President, Europe. Previously president of the Italian Space Agency and a senior propulsion and aerothermodynamics leader at ESA.

Sid Hariharan is listed by Vast as Chief Financial Officer. Investment banking experience at Rothschild and J.P. Morgan includes mergers, public offerings and capital raising.

Caryn Schenewerk is listed by Vast as Chief Policy Officer. Specialist in commercial space policy, regulation, government affairs and legal compliance.

Andrew Feustel is listed by Vast as Lead Astronaut. Former NASA astronaut and astronaut-office leader with missions to the International Space Station and Hubble telescope.

Karin Kuo is listed by Vast as Chief People Officer. People and talent leader with experience at Relativity Space and Onica and in management consulting.

Kris Young is listed by Vast as Chief Operating Officer. Previously led SpaceX Dragon engineering, integration and crewed mission operations, including Demo-2 and Inspiration4.

Max Haot is listed by Vast as Chief Executive Officer. Previously founded Launcher, Mevo and Livestream, subsequently acquired by Vast, Logitech and IAC/Vimeo respectively.

Mette Frich is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Matilde Bødker Verdoes is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mathias Holm Tveen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Martin Søndergaard is published by Innovation Fund Denmark as Head of Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Martha Broegaard Simonsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marion Søvndal de Wit is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marie Louise Lund Stentoft is published by Innovation Fund Denmark as HR Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marie Friis Madsen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Maja Kofod Dam-Jensen is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Maija Strala Ibsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Magnus Ugilt Rasmussen is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mads Trabjerg Kamp is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lise Skjødt Sørensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Line Skouboe is published by Innovation Fund Denmark as Communication Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lene Skovsgaard is published by Innovation Fund Denmark as Head of HR & Organisation. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lars Zederkof is published by Innovation Fund Denmark as Head of Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lakshna Arunasalam is published by Innovation Fund Denmark as Finance Officer (Parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristoffer Nørmark Thrane is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristian Tommy Solberg Ambrosius is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristian Søndergaard Hansen is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Klaus Bruun Gunnestrup is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Katrine Boeriis is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jesper Lykkeberg Sørensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jens Bech-Larsen is published by Innovation Fund Denmark as Head of Jura & Compliance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jasper Kloster Pingel is published by Innovation Fund Denmark as Legal Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Stefan Fyhn Gregersen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing Falck since2026. Advanced emergency-medical-technician training and published Falck Denmark board affiliation.

Jakob Schmidt Sejling is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Gustav Rømsgaard is published by Innovation Fund Denmark as Student Assistant, International & Missioner. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mikkel Helmer Nielsen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing Falck since2022, with technology and emergency-service governance experience.

Katja Barnkob is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing ALK since2022. Pharmaceutical CMC-development project leader with published ALK board affiliation.

Henrik Sindal Jensen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing H.Lundbeck since2022. Chemistry BSc, molecular-biology MSc and neuroscience PhD; pharmaceutical business-development experience.

Eva Ladekjær Larsen is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Eva Hansen is published by Innovation Fund Denmark as Head of Executive Secretariat, Communication & External Relations. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Emma Kloster Nikolajsen is published by Innovation Fund Denmark as Legal Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Elsebeth Hansen is published by Innovation Fund Denmark as Compliance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Ditte Schmidt Jeppesen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Thomas Mrsic-Flogel is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2026 and research/prize committee member. Sainsbury Wellcome Centre director/UCL neuroscience professor; systems-neuroscience, sensory-processing, learning and decision-making research.

Thomas Mears Werge is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2023 and research/prize committee member. Copenhagen clinical-medicine professor and biological-psychiatry research chief, with psychiatric genetics/epidemiology and international programme experience.

Svend Andersen is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2020 and investment-committee member. Business/economics and business-administration education; international pharmaceutical leadership and advisory experience in women’s health and CNS.

Nawal Ouzren is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2025 and investment-committee member. UTC chemical-engineering MSc; Sensorion CEO with clinical-development and pharmaceutical management experience.

An aerospace engineer, former Air Force pilot and aviation regulator appointed as a commercialization advisor in an April 2025 company announcement. Current membership is not confirmed in the live roster.

An aircraft designer and blended-wing-body pioneer who co-founded JetZero. The company’s April 2023 release identified him as CTO; that executive capacity is not confirmed by the current roster.

A supply chain manager at JetZero, publicly identified in the company’s team directory.

An aerospace and defense executive who formerly led Spirit AeroSystems, held senior Boeing roles and served as Acting US Secretary of Defense.

An investor and creative executive formerly CEO of Activision, with advisory experience in technology and aerospace companies.

B Capital’s General Partner and Global Head of Energy, with investment and operating experience in energy and industrial technology. Current primary B Capital biography reviewed October8,2026: With nearly 25 years of investment, entrepreneurship and corporate experience across energy and technology, Jeff most recently served as a Managing Director at Temasek, where he led the US-based investment team focused on energy and industrial growth investments deploying >$1b of capital. Previously, he ran a boutique advisory business focused on scaling sustainable businesses. He also co-founded and was on the Board of Xpansiv, the world’s leading provider of market infrastructure for environmental commodities. Earlier in his career, Jeff worked in innovation business development at ABB, leading growth initiatives for new sustainable products and services, and held leadership, business development and technical roles at Better Place, Vendavo and Intel Corporation. Jeff earned a BS in Industrial Engineering from University of Florida and an MS in Engineering Systems from the Massachusetts Institute of Technology.

An aviation and travel investor, Volaris co-founder and DiamondStream Partners co-founder, with earlier consulting and operating experience.

An aerospace structures specialist and former Gulfstream executive and chief scientist, with experience in aircraft static analysis and fatigue.

Advises on business management, drawing on aerospace operations, government contracts and aircraft-company leadership experience.

A Stanford aerodynamics researcher and founder of ZeeAero, with experience in early blended-wing-body research and aircraft design.

A blended-wing-body co-inventor and aircraft advanced-concepts specialist with experience at McDonnell Douglas and Boeing.

An aircraft design and development executive formerly at McDonnell Douglas and Gulfstream, with experience on the MD-80, MD-90 and Gulfstream programs.

An aircraft program executive known for leading development, certification and delivery of the CSeries/A220; also advises JetZero technically and serves on its board.

An aircraft sales and leasing executive and founder of JetStar Partners, with experience in asset management and aviation policy.

A former president of Bombardier Business Aircraft and Gulfstream Aerospace experienced in bringing business jets into service.

An aviation executive with experience at Pratt & Whitney and aerospace industry organizations; listed on JetZero’s advisory board.

An aviation executive experienced in airline leadership and fleet advisory work; listed on JetZero’s advisory board.

An aviation executive with prior aircraft and engine industry leadership; listed on JetZero’s advisory board.

A former FAA administrator, Air Force pilot and Delta executive advising JetZero on aviation matters.

An aviation executive who previously led Learjet, Galaxy Aerospace and Aerion, and served in the US Air Force.

An aerospace customer-engagement executive with experience in systems engineering, aftermarket sales and connected-aircraft technology at Gulfstream.

A flight-controls engineer experienced in fly-by-wire systems and avionics development at Thales and on Gulfstream aircraft programs.

Leads security, with prior intelligence and security operations experience at the World Bank and major companies.

An aerospace propulsion leader with experience in Boeing commercial and defense programs, advanced concepts and defense strategy.

Leads structures engineering, with experience developing large composite aircraft structures across commercial and defense platforms.

Leads market development and sales engineering, drawing on aerospace research and advisory experience at Frost & Sullivan, G2 Solutions and AIR.

Works across aerospace policy and government affairs, with experience in Boeing advocacy, consulting and US government trade and national-security functions.

Leads company communications, with prior commercial aviation communications roles at RTX, Qatar Airways, JetBlue, TWA and Delta.

A graphic and product designer with experience in branding, software and design systems at Atari, Acquia and BETA Technologies.

Leads workplace innovation and campus experience across headquarters and manufacturing facilities, with a background in industrial design and corporate environments.

Oversees JetZero’s Long Beach campus, including facilities, security and employee wellness, following roles in automotive and technology startups.

An aircraft cabin and product designer experienced at Zodiac Aerospace, BMW Designworks and Safran, and co-founder of Applied Mobility Partners.

An engineer experienced in propulsion integration, aircraft systems and flight operations, previously at GE Aviation and Virgin Orbit.

A people leader with accounting and business analytics training and prior financial-management experience at ICON Aircraft.

Leads the full-scale demonstrator program and previously served as a Navy pilot, test pilot and commander of Naval Air Systems Command.

An aerospace supply-chain leader with prior roles on Space Shuttle, Gulfstream, HondaJet, HAECO and Northrop Grumman programs.

An engineering executive experienced in aircraft development, testing, manufacturing and support at Rolls-Royce, Bombardier and Airbus.

Leads the commercial Z4 program and certification, combining aircraft systems experience, pilot qualifications and aerospace engineering training.

An aviation support and aftermarket executive with experience in aircraft leasing, maintenance, manufacturing and technical services.

An aerodynamics specialist and former Boeing Phantom Works chief aerodynamicist who developed aircraft efficiency improvements.

An attorney with experience in finance, commodities and global commercial legal operations, previously at Mastercard.

Leads business operations, with a background in systems engineering and program management at Boeing, Gulfstream and Naval Air Systems Command.

An aerospace product and design leader with experience in engineering, operations, sales and cabin-product innovation at Zodiac Aerospace and Safran.

A corporate executive experienced in scaling technology, defense, autonomous systems, consumer electronics and platform companies through growth and financing.

An aviation finance executive with experience across aircraft manufacturing, airlines, leasing and capital providers, including Airbus, AerCap and Wisk.

An aerospace engineer and commercial aviation executive with experience at Embraer, Douglas Aircraft and Boeing.

Previously worked in automotive and technology startups and was COO of BETA Technologies; co-founded JetZero with aircraft designer Mark Page.

Daniel Green Blok Marques is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cæcilie Hougaard Pedersen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Christian Frost is published by Innovation Fund Denmark as Senior Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Charlotte Vinther Bertelsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilie Würtz Krog is published by Innovation Fund Denmark as Legal Officer (parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Esmeralda Lewis is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilie Uldall Duch is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Morten Hummelmose is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2025 and investment-committee member. Copenhagen economics and London finance masters, with private-equity/investment leadership background at EQT.

Michael Kjær is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2016, research/prize committee member and clinical sports-medicine professor/chief physician affiliated with Bispebjerg and Copenhagen. Musculoskeletal/metabolic research and research-management experience.

Lars Holmqvist is listed by the Lundbeck Foundation as Deputy Chair. Foundation board member elected2015 and Deputy Chair. International medtech/pharma leadership and commercial/finance experience; published investment-committee membership.

Søren Skou is listed by the Lundbeck Foundation as Chair. Foundation board member elected2024 and current Chair, with investment-committee leadership. Copenhagen business/economics degree and IMD MBA; international corporate, infrastructure and governance experience.

Isabelle Zenklusen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilie Tordrup Andersen is published by Innovation Fund Denmark as Executive Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilie Brøkner is published by Innovation Fund Denmark as Chief Executive Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Karina Jeppesen Morgen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilia Elise Kaas Rutherford is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anne Kathrine Nissen Pedersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Caroline Sofie Gundestrup is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Camilla Trothe Mygind is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Linda Lomholt Petersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Lone Michelsen is listed by the Lundbeck Foundation as Service Coordinator. Current named Service Coordinator. Own detailed academic/career biography is unpublished.

Kenneth Lütken Rode is listed by the Lundbeck Foundation as Office Manager. Administrative/service professional with earlier finance, operations, marketing and HR work, including SAS cabin-service experience.

Frederik Madsen is listed by the Lundbeck Foundation as Manager, Sustainability. Former PwC finance/sustainability consultant and Terma performance-management professional. Aarhus business qualification; focuses on sustainability strategy/reporting.

Rasmus Thomsen is listed by the Lundbeck Foundation as Head of Sustainability and Strategy. Former Danish Export and Investment Fund strategy leader, Danish Finance Ministry professional and Brussels diplomat. Copenhagen political-science MSc and London School of Economics masters; works across sustainability and investment strategy.

Børge Lindberg is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Trine Juul Wengel is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Bodil Therese Lundstrøm Bang is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Max Siller is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Bo Billeskov Grünberger is published by Innovation Fund Denmark as Communication Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Asger Narud is published by Innovation Fund Denmark as Head of International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anders Ulv Mandsholm is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Jesper Friese is listed by the Lundbeck Foundation as IT Manager. Joined January2019 after fifteen years at ITR Data in system administration/development. TEC Ballerup and Niels Brock training; manages daily IT operations.

Helle Rejkjær is listed by the Lundbeck Foundation as Accountant. Current Finance Accountant. Own detailed academic/career biography is unpublished.

Sune Nordby Madsen is listed by the Lundbeck Foundation as Controller. Current Finance Controller. Own detailed academic/career biography is unpublished.

Lotte Halse is listed by the Lundbeck Foundation as Investment Controller. Joined Lundbeckfond Invest finance2012 after asset-management support and administration leadership at Gudme Raaschou, Straumur and ATRIUM.

Arne Nielsen Skov is published by Innovation Fund Denmark as Senior Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Steen Saaby is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anne-Mette Iversen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anne Sofie Bramsen Dahlmann is published by Innovation Fund Denmark as Relations Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anne-Marie Larsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Andrea Bøcker is published by Innovation Fund Denmark as HR Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Joanna Krzynowek is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Alva Hebe Sørensen is published by Innovation Fund Denmark as Student Assistant, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Olufunke Adebiyi is listed by the Lundbeck Foundation as Head of Tax. Joined2024 as Head of Tax after PwC Nigeria/Denmark and VKR Holding roles. ACCA fellow with tax/compliance experience; published short name Funke.

Søren Christiansen is listed by the Lundbeck Foundation as Senior Vice President, Finance. State-authorised public accountant and former EY/KPMG audit/advisory partner; leads finance, accounting, tax and IT.

Jurij Radzevic is listed by the Lundbeck Foundation as Digital Marketing Specialist. Joined September2025 after technology-startup marketing work. Southern Denmark marketing/globalisation/communication masters and international study/work experience.

Victor Ortega is listed by the Lundbeck Foundation as Political Consultant. Current Political Consultant in Public Affairs. Own detailed academic/career biography is unpublished.

Jürgen Brem is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Alexander Sienczak Knudsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Alberte Kring Korsgaard is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Camilla Tvede Schytz is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Aila Lonka is published by Innovation Fund Denmark as Head of Finance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marlene May Vestergaard is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Kasper Riis is listed by the Lundbeck Foundation as Head of Communications. Joined January2024 after Nets, Tryg and life-science communications roles involving Nycomed, Novo Nordisk Engineering and Lundbeck. Roskilde communications/geography BA and journalism training.

Gitte Grove Stig is listed by the Lundbeck Foundation as Senior Manager, Outreach and Partnerships. Joined April1,2018 with earlier pharmaceutical medical-marketing and event/partnership experience. Coordinates outreach and university relationships.

Margrethe Nabe-Nielsen is listed by the Lundbeck Foundation as Director of Public Affairs & Signature Projects. Joined August2020 with earlier Danish Ministry of Education, volunteer-council and scout-association public-affairs experience. Copenhagen political-science masters.

Maria Nymark Jensen is listed by the Lundbeck Foundation as HR Consultant. Joined2025 after Copenhagen Business Academy HR partnership and ATP HR-specialist work; supports people processes, wellbeing and events.

Laurane Mackels is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Karen Wibe Enevoldsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Founder of iGnosis Capital and former CEO & Chairman of Inmar Intelligence, which he led through three PE recapitalizations and 15+ acquisitions. Earlier, CFO of UPS Supply Chain Solutions and EVP & CFO at Domino’s.

Mette Eistrøm Krüger is listed by the Lundbeck Foundation as Senior Vice President, People & Corporate Affairs. Joined March2025 following Telenor Nordic and Danish people/corporate-affairs leadership. Aalborg business-law qualification; leads HR, communications and public affairs.

Christina Polyzogopoulou is listed by the Lundbeck Foundation as Student Analyst. Joined April2025. Aristotle University Thessaloniki biology degree, multimedia/web-development study and current IT University Copenhagen software-design masters; supports Neurotorium technical and creative work.

Maika Pedersen is listed by the Lundbeck Foundation as Student Analyst. Joined January2026. King’s College London neuroscience/psychology degree and current Copenhagen Business School digital-business masters study; supports Brain Prize programmes.

Terese Vibe Boye is listed by the Lundbeck Foundation as Student Analyst. Joined September2025 alongside Copenhagen public-health masters study. Earlier innovation/medical-affairs and Danish Embassy London life-science work; supports Neurotorium content and communications.

Lone Lund is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Hang Nguyen Nielsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Michael Dyrgaard Lundov is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anne Sofie Danekilde is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Alok Singh is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Sidsel Dan Hull is listed by the Lundbeck Foundation as Grant Manager. Joined September2026 after an earlier foundation student-analyst term2018–2022. Copenhagen public-health masters and environmental-epidemiology PhD; administers applications and reporting.

Ulla Vig Nissen is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined August2026 from Novo Nordisk Foundation. Earlier neuroscience research at Oslo/Karolinska/Copenhagen, spinal-cord rehabilitation work, SSI/DTU grant support and medical-device project management. Copenhagen biology MSc and Oslo neuroscience Dr.philos.

Louise Bruun is listed by the Lundbeck Foundation as Executive Assistant. Joined March1,2018 after executive-assistant roles involving ATP, Danish ministries and the Royal Court. Supports science leadership, Brain Prize and Neurotorium administration.

Niels Hoffmann Haahr is listed by the Lundbeck Foundation as Grant Manager. Joined January2025 after health-science administration and nine years of Danish Patient Compensation casework. Aarhus ethnography/social-anthropology masters with medical-anthropology focus; administers grants/data through LANAS.

Maja B. Nielsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Karen Hue is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilia Sparr Eskilsson is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Karen Nørby á Rógvu is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Bryn Farnsworth von Cederwald is listed by the Lundbeck Foundation as Scientific Programme Manager, Neurotorium. Joined April2024 after aging/dementia research at Nottingham, Uppsala and Umeå and science-communication work in behavioural-research software. Sheffield MSc and Uppsala PhD.

Nanna Junker is listed by the Lundbeck Foundation as Senior Scientific Programme Manager, Frontier Grants. Joined January2023 with academic/industrial preclinical and translational project-management experience. Natural-sciences masters and Copenhagen PhD; supports Frontier Grants.

Ceren Akdeniz Vogt is listed by the Lundbeck Foundation as Head of Neurotorium, Outreach and Partnerships. Joined March2023 after medical-science industry roles. Tübingen neural/behavioural-science MSc and Heidelberg psychiatry doctorate; leads Neurotorium scientific content, partnerships and outreach.

Julie Marie Brandt is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined February2024 after outpatient psychiatry, clinical research and Danish Police psychology work. Copenhagen psychology MSc and psychiatry PhD; develops clinical-psychiatry initiatives.

Henriette Natorp Tobiesen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Mette D. E. Jepsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Signe Rode Andreasen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilie Kirkeby Skeby is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Teresa Gidaro is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Line Vildbrad Kristensen is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Foundation employee2017–2022, BioInnovation Institute Principal2023, returned January2024. Aarhus medicinal-chemistry masters and Copenhagen/Lundbeck industrial PhD; supports brain-health and open/Frontier grant programmes.

Anette Høye is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined July2018 after Copenhagen postdoctoral research. Syracuse BSc and Copenhagen human-biology MSc/PhD; handles science engagement and investigator-network programmes.

Paul Kristjansen is listed by the Lundbeck Foundation as Senior Scientific Director, Frontier Grants. Joined August2022 after Lundbeck licensing/M&A and research/clinical-development roles involving Copenhagen, Harvard and Novo Nordisk. Copenhagen MD/PhD/DMSc; oversees translational Frontier Grants.

Peter Thostrup is listed by the Lundbeck Foundation as Scientific Programme Director, Open Programmes. Joined June2021 following Carlsberg Foundation secretariat leadership2016–2021 and earlier Aarhus/McGill research. Aarhus physics MSc/PhD, with neurobiology postdoctoral work; manages open-competition programmes.

Morten Dahl Sørensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Dorthe Bach Toft is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Vera Kiyasova is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Thomas Breuer is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Martin Meyer is listed by the Lundbeck Foundation as Scientific Programme Director - The Brain Prize and Neurotorium. Joined2020 after King’s College London neuroscience group leadership and Stanford postdoctoral research. University College London biology degree and cell/developmental-biology PhD; oversees Brain Prize and Neurotorium.

Lars Torup is listed by the Lundbeck Foundation as Scientific Programme Director - Strategic Programmes. Joined March2018 from Novo Nordisk Foundation after sixteen years of Lundbeck neurology/psychiatry drug research. Copenhagen biochemistry MSc and neuropharmacology PhD; develops neuroscience initiatives.

Jan Egebjerg is listed by the Lundbeck Foundation as Senior Vice President, Grants & Prizes, Director of Science. Joined August2019 after CNS research and management at Lundbeck, Janssen and Novo Nordisk, with earlier Aarhus molecular-biology academic affiliation. Aarhus masters/PhD; oversees philanthropic science grants and prizes.

Gustav Brøbecher Thorndahl is listed by the Lundbeck Foundation as Student Analyst. University of Copenhagen law student with earlier law-firm student experience; supports legal work and the management office.

Niels Chr. Felumb is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Caitlin Cornwall is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Beatriz Sevilla-Jensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anette Kjær Petersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Emil Bernekilde Andreasen is listed by the Lundbeck Foundation as Digital AI Consultant. Former IT consultant at Visma Consulting and Twoday. Copenhagen Business School Digital Business masters; supports AI assistants, automation, process design, implementation and training.

Mette Line Braad is listed by the Lundbeck Foundation as General Counsel. Current General Counsel. Own profile does not publish a detailed career or academic biography.

Anette Mullerup Schmidt is listed by the Lundbeck Foundation as Executive Assistant to the CEO. Joined March1,2023 after executive-assistant positions at Ørsted, Rambøll, Maj Invest and Accenture; supports the CEO and foundation board.

Lene Skole is listed by the Lundbeck Foundation as Chief Executive Officer. Foundation CEO since2014. Previously Coloplast CFO2005–2014 and Maersk Company Ltd CFO2000–2005; studied at Copenhagen Business School, London Business School and IMD. Published governance experience spans healthcare, energy and banking.

Jesper Emil Jakobsgaard is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Pernille Bogetofte Thomasen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Stine Krag Brunvold is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Thomas Skjærlund Grønnebæk is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Michael Voldsgaard Clausen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Gabrielle Chappell is listed by the Lundbeck Foundation as Associate. Current named BioCapital Associate. Own detailed career and education biography is unpublished; published directory image is a foundation-logo placeholder, not a portrait.

Jette Brandsen Bundgaard is listed by the Lundbeck Foundation as Executive Assistant & Facility Manager. Joined2014 after executive-secretarial work at Bispebjerg Hospital and Danske Bank/Danske Securities. Qualified legal and medical secretary; supports unit administration and partners.

Jan-Erik Messling is listed by the Lundbeck Foundation as Principal. Former BCG biopharma/medtech consultant with earlier Danish/German cancer and stem-cell research. Cologne biological-sciences MSc and Copenhagen molecular-disease PhD.

Liane Dupont is listed by the Lundbeck Foundation as Principal. Earlier molecular and clinical coronavirus researcher at King’s College London. Copenhagen molecular-biomedicine BSc and Cambridge medical-sciences MRes/PhD; current own board-observer affiliations are separately qualified.

Trine Böenche Sørensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Nicole Nicolajsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Robert Law was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Katja Krustrup Pedersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Matt Suminski was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Paolo Joaquim dos Santos was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Lilou Marchand was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Peter Bentsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Martin Dominguez was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Antoine Moreno was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Nisha Marathe is named as Investment Director in South San Francisco in the original Roche2023 presentation. Her self-published professional profile continues to show an RVF affiliation, but she is absent from the current five-person corporate directory. This record preserves the historical publication without guessing a departure or asserting a current title.

Kevin Dalgaard is listed by the Lundbeck Foundation as Senior Principal. Former Novo Nordisk R&D, marketing and business-development professional. University of Copenhagen biochemistry MSc and Max Planck Institute PhD, with published molecular-biology research.

Lars Gredsted is listed by the Lundbeck Foundation as Partner. Earlier AstraZeneca/MedImmune business development, Wellcome Trust life-science investing, Oxford biotechnology and BCG consulting. Copenhagen biochemistry masters, Heidelberg/EMBL PhD and Cambridge MPhil. Current directory says Partner while an older biography paragraph still says Senior Principal; directory controls current title.

Jacob Falck Hansen is listed by the Lundbeck Foundation as Partner. Former Novo Nordisk corporate-strategy head with fifteen years across pharma strategy and leadership advice. University of Copenhagen biochemistry MSc/PhD and research-publication background. Own biography identifies Vesper Bio CEO and several board/observer affiliations; no personal investment is inferred. Jacob Falck Hansen is currently listed by Vesper Bio as CEO. Previously led Novo Nordisk corporate strategy and holds Copenhagen biochemistry MSc/PhD; appointed Vesper CEO July2025.

Anasse Laafou was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Kamilla Løhde Tordrup Dybdahl is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Mohamed Aziz Omri was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Narimane Gassa was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Marianne Gerberg Skals is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Carole Nuechterlein is named as Head of Roche Venture Fund in its original2023 presentation. The current primary directory names Anja Harmeier as head. This historical leadership record is explicitly qualified; exact departure day is not established.

Kirushini Satkunaseelan was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Jeppe Blichfeldt Winther is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Eléa Robert was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Simon Greenwood is a Senior Investment Director in Roche’s current published venture-fund directory. COUR’s own board biography independently names the same RVF role. The original Roche2023 presentation places him in South San Francisco. Company board affiliation does not establish a personal cash investment.

Pauline Migerditichan was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Louise-Amélie Schmitt was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Rasmus Thoning is listed by the Lundbeck Foundation as Investment Associate. Corporate-finance adviser with M&A, capital-structure and valuation experience, including earlier Nrep real-estate transactions. Copenhagen Business School economics/business BA and current finance/accounting masters study.

Anna Jul Bjørn is listed by the Lundbeck Foundation as Investment Associate. Former Nordea equity researcher covering Nordic financial institutions. Copenhagen Business School finance/accounting masters.

Per Hajslund Mayo is listed by the Lundbeck Foundation as Associate Director. Joined May1,2021 after Danske Bank equity research and Nykredit M&A advisory in energy/infrastructure. Copenhagen Business School finance/strategic-management masters.

Steen Walther Jensen is listed by the Lundbeck Foundation as Senior Investment Director. Joined June1,2020 following Danske Bank asset-management and strategy work and earlier Gudme Raaschou/Kaupthing corporate finance. Copenhagen Business School finance/accounting MSc.

Nicholas Kelly is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Thomas Queuche is named as RebrAIn’s Quality and Regulatory Affairs Manager in its July2024 FDA submission for OptimMRI v2 and as Data Protection Officer in the company’s published privacy policy. Its own January2025 post also names him in its professional team. Exact current operating title continuity is distinguished from these published dates.

Dorothee Uriet was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Antoine d’Humières was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Nete Huus is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Gabriella Zöch is Project Manager in Roche’s current published venture-fund team. The original Roche2023 presentation also names her in project management in Basel. Exact tenure dates and further professional biography are not publicly verified.

Teddy Wan is publicly named by Cormorant Asset Management as deputy general counsel. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Dana Varinos is publicly named by Cormorant Asset Management as data operations associate. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Keaton McKernan is publicly named by Cormorant Asset Management as controller. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Garrett McGlory is publicly named by Cormorant Asset Management as finance manager. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

John Coners is publicly named by Cormorant Asset Management as director of investment analytics. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Bita Sehat is May Health’s director. The company publishes this current affiliation on its own team and board page.

Robert Auerbach is May Health’s board chair. The company publishes this current affiliation on its own team and board page.

Anne Bubb is May Health’s vice president, marketing. The company publishes this current affiliation on its own team and board page.

Ross W. McQuivey is May Health’s chief medical advisor. This is an advisory role published on the company’s own current team page.

Cindy Domecus is May Health’s chief regulatory advisor. This is an advisory role published on the company’s own current team page.

Connie Rey is May Health’s vice president, clinical affairs. The company publishes this current affiliation on its own team and board page.

Aruna Akkapeddi is May Health’s vice president, quality assurance/regulatory affairs. The company publishes this current affiliation on its own team and board page.

Hugh E. Magen is May Health’s chief technical officer. The company publishes this current affiliation on its own team and board page.

Colby Holtshouse is May Health’s president, chief executive officer and director. The company publishes this current affiliation on its own team and board page.

Poul la Cour is listed by the Lundbeck Foundation as Senior Investment Director. Joined2015 after Novo Nordisk corporate strategy and FIH/Carnegie research roles. Copenhagen Business School finance/accounting MSc; co-manages financial investments.

Nikolaj Frederik Kamedula is listed by the Lundbeck Foundation as Senior Investment Director. Joined2019 after Danish Ship Finance, FIH, SEB and Nordea Asset Management roles. Holds economics masters and focuses on listed equities and credit.

Peter Rothausen is listed by the Lundbeck Foundation as Senior Vice President, Financial Investments and Head of Invest. Joined May1,2018 after Danske Capital portfolio leadership and earlier Carnegie/FIH/Danske Bank equity research. Copenhagen Business School finance/accounting MSc.

Rasmus Linde Larsen is listed by the Lundbeck Foundation as Associate. Earlier PwC financial due-diligence/M&A work. Copenhagen Business School finance/accounting masters; supports healthcare ownership analysis and new strategic investments.

Anders Findsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Victor Schmelzer is a member of CardioRenal Systems’ Scientific Advisory Board. The company identifies him as a cardiovascular surgeon at St. Elizabeth Healthcare with experience in complex heart surgery.

Todd Rosengart is a member of CardioRenal Systems’ Scientific Advisory Board. His issuer biography identifies him as a surgical chair at Baylor College of Medicine and Texas Heart Institute with cardiac-surgery clinical research experience.

Dan Engelman is a member of CardioRenal Systems’ Scientific Advisory Board. The issuer identifies him as a cardiothoracic surgeon and medical director at Baystate Medical Center and head of the Enhanced Recovery After Surgery Society.

Jacob Raphael is a member of CardioRenal Systems’ Scientific Advisory Board. The issuer identifies him as an anesthesiologist at Thomas Jefferson University Hospital researching perioperative care and prevention of acute kidney injury after cardiac surgery.

Richard Solomon advises CardioRenal Systems on its Scientific Advisory Board. The issuer identifies him as a University of Vermont nephrology professor with acute-kidney-injury clinical-trial and biomarker research experience.

Avi Wise directs business operations at CardioRenal Systems. His published experience includes healthcare innovation analysis at Imagine Bio and business-development and operations projects; he studied biology at Northland College.

Tzvi Stern is CardioRenal Systems’ chief financial officer. His biography describes finance work in technology and biotechnology, transactions at Regenocell Labs and Magnifire, and earlier accounting at KPMG.

Robin Luper leads international sales at CardioRenal Systems. His issuer biography describes medical-device sales and international distribution experience and the launch and growth of Acist sales.

Janice Hogan is a regulatory adviser to CardioRenal Systems and a partner at Hogan Lovells. The issuer biography describes experience guiding medical devices through FDA review and engineering and law degrees from MIT and Georgetown.

William Denman, published with the nickname Pepper, advises CardioRenal Systems on medicine and industry. His biography lists previous chief medical officer roles at Covidien, GE Healthcare and Cheetah Medical and anesthesiology at Massachusetts General Hospital.

Shmulik Adler leads clinical and regulatory affairs at CardioRenal Systems. His published medtech experience includes clinical trials and regulatory work at Nucleix, Oridian and Brainsway.

Laura Dern is published as president in CardioRenal Systems’ management directory. The company does not publish a career biography for this person.

Heyman Luckraz leads medical affairs at CardioRenal Systems. He is a cardiothoracic surgeon with UK and UAE clinical experience and involvement in the RenalGuard cardiac-surgery validation study.

Ethan Benovitz is chairman of CardioRenal Systems. His published biography describes more than twenty-five years investing in healthcare and technology and an earlier corporate-law career after Harvard Law School.

Ilya Budik leads CardioRenal Systems as CEO. His published experience includes healthcare product and business strategy at Imagine Bio and leadership of NeuroQuest; he studied finance and biochemistry at Miami University.

Jay Riccio is publicly named by Cormorant Asset Management as head trader. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Sarah Roxe is publicly named by Cormorant Asset Management as director of investor relations. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Neb Obradovic is general counsel and chief compliance officer of Cormorant Asset Management. The current official roster and genuine named portrait match the May 2026 SEC legal name Nebojsa Obradovic, with the compliance/general-counsel role dated January 2016. The shortened professional name and legal name refer to the same published manager role.

Caleb Tripp is chief financial officer and chief operating officer of Cormorant Asset Management. Its current official roster publishes his named portrait; the May 2026 SEC filing identifies the same Caleb Jonathan Tripp and dates the CFO/COO role to August 2020. The role concerns manager operations and financial oversight.

Bihua Chen founded Cormorant Asset Management in 2013 and is its current chief executive officer and chief investment officer. The May 2026 SEC filing identifies her as managing member and CEO since March 2013. She oversees a biotechnology and healthcare strategy spanning public and private companies. Fund-control and voting authority are institutional legal roles, not automatically personal investment checks. A 2026 issuer proxy records a Fudan genetics and genetic-engineering degree, a Cornell molecular-biology master’s and a Wharton MBA, alongside earlier healthcare analyst and portfolio-management roles.

Jean Régis is listed on RebrAIn’s published scientific/medical advisory board, with affiliation APHM, Marseille.

Shayan Moosa is listed on RebrAIn’s published scientific/medical advisory board, with affiliation University of Virginia, Charlottesville.

Dorte Olsson is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Charles Munyon is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Charlotte Novant Health.

Michael J. Kinsman is listed on RebrAIn’s published scientific/medical advisory board, with affiliation University of Kansas Hospital, Kansas City.

Joohi Jimenez-Shahed is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Mount Sinai, New York.

Jeanette Jeppesen Morgen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Founder, president, CEO and director of Ascendis Pharma, with earlier leadership at LifeCycle Pharma, Maxygen and ProFound Pharma and protein-discovery experience at Novo Nordisk. His university training is in biochemistry at Odense. Aarhus University’s2015 NeuronIcon closure account identifies him among its founders; that corporate attribution is historical and does not establish a personal funding ticket.

Anna Emilie Møller Koefoed is listed by the Lundbeck Foundation as Associate. Joined2020; focuses on financial and strategic analysis of healthcare ownerships. Copenhagen Business School finance/accounting qualification. Own current biography qualifies maternity leave.

Rasmus Giese is listed by the Lundbeck Foundation as Associate Director. Earlier ABG Sundal Collier investment-banking/M&A work and CS Capital private-equity experience. Copenhagen Business School finance/accounting masters.

Louise Lind Ladegaard is listed by the Lundbeck Foundation as Senior Director. Earlier Danske Bank corporate finance and ISS M&A/transformation work; holds University of Copenhagen economics masters.

Arne Due-Hansen is listed by the Lundbeck Foundation as Senior Vice President, Strategic Ownerships. Responsible for strategic investments fromSeptember2022. Earlier Alfred Berg analyst/corporate-finance work, SEB investment-banking leadership1997–2013 and Danske Bank strategic M&A advisory from2014. Copenhagen Business School finance/accounting masters.

Lain Hermes González is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Clínica Universidad de Navarra, Spain.

Rees Cosgrove is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Brigham and Women’s Hospital, Boston.

Max Delbrück Center scientist leading Molecular Cardiovascular Research, studying intracellular sorting receptors, metabolism and Alzheimer’s disease. His training includes biology/biochemistry in Munich and postdoctoral research at UT Southwestern. Capnova identifies his research as a foundation of NeuronIcon; the International Society of Nephrology’s2011 biography explicitly names him the company’s chief scientific officer. These corporate capacities are historical, not current employment at a closed company.

Ausaf A. Bari is listed on RebrAIn’s published scientific/medical advisory board, with affiliation UCLA Brain Research Institute, Los Angeles.

Vibeke Uhre is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

RebrAIn CEO appointed in the March18,2024 financing announcement, formerly Theraclion CEO with earlier leadership at GE Healthcare. Current French registry identifies him as statutory Président de SAS, distinct from the company directory’s board-president title for Emmanuel Cuny.

Aarhus University biomedicine professor and PROMEMO research leader studying neuronal communication, memory and receptor biology relevant to psychiatric disorders. Contemporary university sources identify his2004 co-founding of NeuronIcon, and the university’s2015 closure notice identifies him as its former leader. His academic laboratory is distinct from the closed company. Anders Nykjær is currently listed by Vesper Bio as FOUNDER AND CSO. Scientific founder and chief scientific officer, researching sortilin and neuronal receptor biology; Aarhus academic biography and existing external roles preserved.

Inria researcher in applied mathematics and RebrAIn co-founder. Its current directory identifies him as CSO and CTO and reports 100 publications in mathematical inverse problems; the French registry separately lists him as Directeur Général.

Professor of neurosurgery at Bordeaux University Hospital and co-founder of RebrAIn. Its current company directory identifies him as Chief Medical Officer and board president; the French legal registry separately lists him as Directeur Général.

Tina Klitte Holmstrøm Lohmann is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Martin Gruwier Broch-Lips is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Jean-Pierre Renaudin is identified by NACO as its president in a June18,2025 statement. His published account describes regional innovation, industrial development, business transmission and long-term territorial investment. The sourced NACO presidency is distinguished from the external M Capital deployment team; no unrelated namesake biography or additional political office is assumed.

Marius Branger is publicly listed by M Capital as Analyste Financier - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Jean-Baptiste Bourhis is publicly listed by M Capital as Responsable d'Investissement - Dette Privée. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Aïcha Helal is publicly listed by M Capital as Chargée de Relations Partenaires Clients. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Florent Pouey is publicly listed by M Capital as Analyste Financier - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Dina Raharolahy is publicly listed by M Capital as Comptable. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Guillaume Gorski works on real-estate financial analysis, valuations, quarterly reporting and investor communications at M Capital. An ESPI graduate, he previously worked in Paris property investment, Montreal construction consulting and investment leadership at Wiseed.

Chaïma El Alaoui El Ismaili is publicly listed by M Capital as Chargée Conformité. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Murielle Rembliere is publicly listed by M Capital as Assistante Juridique. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Pierre Monnin is publicly listed by M Capital as Chargé d'Affaires - Private Equity. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Adrien Raphet joined M Capital in 2021 to develop public-client financing for Fonds Tourisme Occitanie. His earlier banking experience includes Dexia, Caisse d’Épargne Midi-Pyrénées and La Banque Postale.

Chrystelle Mouligné joined M Capital in 2020 and handles accounting for M Capital Partners and M&Co Conseils. Her published earlier experience includes Scamp TP, Roldan and Merch & Cie.

Olivier Besançon joined M Capital in late 2020 for Fonds Tourisme Côte d’Azur. His background includes fifteen years in corporate and institutional banking at Arkéa and earlier industrial-sector financing. He studied at SKEMA in Sophia Antipolis.

Khaira Benyamina joined M Capital in 2019 and manages client and partner relationships. Her earlier professional experience includes ACOSS and the French Red Cross.

Arnaud Aldegheri joined M Capital’s real-estate investment team in 2021 as a financial analyst. He studied management and finance at Toulouse Business School, with earlier experience in Barcelona financial analysis and Paris property-data research at Rock-n-data.io.

Amélie Guelff-Mariotti joined M Capital in 2020 in compliance and internal control and now manages sustainable finance. She holds a postgraduate business-law qualification and has prior legal-analysis and legal-services experience.

Florian Ricard joined M Capital’s private-debt team in 2019 for Fonds Tourisme Occitanie. He previously spent more than ten years supporting businesses and entrepreneurs at Crédit Agricole, HSBC and Banque Palatine.

Jessica Darmon joined M Capital in 2017 in accounting and compliance support and moved into fund operations in 2019. Her published biography describes a management and finance master’s degree, previous accounting-firm experience and operational support across numerous funds.

Diane Fiocca is publicly listed by M Capital as Chargée d'Affaires. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Théo Hernandez joined M Capital in 2017 as a portfolio analyst and moved into private-equity business development. He studied at Toulouse Business School and previously worked on borrower relationships and financing transactions at October.

Alexandra Begue is publicly listed by M Capital as Responsable de Programmes Immobiliers. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Fabrice Attané-Ferrand joined M Capital in 2019 for Fonds Tourisme Occitanie and moved into NACO deployment in 2022. His corporate-finance background includes PwC and Bpifrance, covering business financing, guarantees and investment products.

Anaïs Custodio manages partner relationships and client experience at M Capital. Her published background includes business development and six years supporting property-development activities at Théseis.

Clément Bauguil joined M Capital in 2017 as a venture and private-equity analyst and now oversees venture participations. He holds a corporate-finance master’s degree from Toulouse School of Management, with earlier experience at Legrand and Volkswagen’s risk division.

Estelle Adam joined M Capital in 2016 and manages legal matters for private debt and private equity. Her work includes fund creation, investments and exits. She holds business-law and DJCE qualifications and previously worked in a law firm and at Latécoère.

Maxime Sauvanet is publicly listed by M Capital as Directeur d’Investissement - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Lucie Pelloux joined M Capital in 2014 and manages digital projects. Her background includes web and multimedia training, agency experience and webmaster responsibilities at Crédit Agricole.

Bertrand Casteran is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

David Richou is publicly listed by M Capital as Directeur d’Investissement - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Marion Laurens joined M Capital in 2014 to support private-equity fund and investment legal work, then moved into property-financing legal responsibilities in 2017. She holds a postgraduate tax-law qualification and previously worked in a law firm.

François-Xavier Belliard is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Christophe Maurel joined M Capital in 2018 and leads Welcome. His published work includes developing entrepreneurial investment platforms and the Good Property and Buildr crowdfunding initiatives.

Hortense Mellinger joined M Capital in 2012 and leads marketing and communications across its brand, investment products and portfolio activities. Her previous experience includes Dim, Pierre Fabre and e-commerce.

Julien Charles-Lavauzelle joined M Capital in 2016 and works on growth-capital and business-transmission investments and portfolio oversight. His published biography describes prior audit experience and membership of the manager’s investment committee.

Lucie Berges-Rosa joined M Capital’s private-equity investment team in 2011 and subsequently worked on portfolio monitoring and valuation. She studied at Bordeaux Management School and completed an MBA at Wake Forest University.

Benoît Thiedey joined M Capital in September 2025 as venture investment director, supporting NACO portfolio deployment and Welcome Entrepreneurs. An investor since 2006, he previously worked at Naxicap and Eiffel Investment Group, built Alliance Entreprendre’s venture team from 2017, and joined Seventure Partners in 2022. He holds a Lyon II master’s degree in business valuation and financial engineering.

Boris Michel is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Marc Trubert develops M Capital’s investment activities. He advised portfolio companies from 2014 and joined the private-equity team in 2019, later supporting Fonds Tourisme Occitanie. His earlier career included 23 years of operating and commercial responsibilities at France Boissons.

Lucile Bardou joined M Capital in 2013 in accounting and became deputy secretary general in 2016. She supports fund operations, accounting and legal administration. Her qualifications include a master’s degree in management control and financial engineering.

Thibault Richebois is publicly listed by M Capital as Directeur Général - M Capital Nouvelle Aquitaine. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Stéphane Ferran joined M Capital in 2017 and is deputy managing director for real estate. An INSA-trained engineer, he previously worked for more than two decades in construction and property development, including SPIE, Akerys and DEDIA.

Julie Khaski leads private debt at M Capital. She joined in 2019 as an investment director for Fonds Tourisme Occitanie and specialises in financing public and private projects. The manager notes her 2023 France Invest recognition for women in private debt.

Karine Maurel leads M Capital’s real-estate business. She joined in 2006 and works on property development, asset management and financing products, including Good Property. Her earlier professional experience includes KPMG, PwC and finance leadership at Sage.

David Aversenq is a managing director and partner at M Capital. He joined its investment team in 2009 after corporate-finance and transaction-advisory work, including six years at PwC. He participated in the acquisition of the manager from Groupe BPCE and studied at Toulouse Business School.

Stéphanie Minissier oversees finance and compliance at M Capital, including management-company and fund controls. Her previous experience includes Synercom, and her published qualifications include the DECF accounting diploma.

Rudy Secco leads M Capital and its investment committees. He acquired the manager from Groupe BPCE and expanded its venture, private-equity, private-debt and property strategies. His earlier career included advisory leadership at KPMG, Arthur Andersen and EY; he studied at Toulouse Business School.

Founding scientist of NMD Pharma, with a 2008 Aarhus physiology and biophysics doctorate. Published research examines muscle sarcoplasmic-reticulum calcium transport and neuromuscular physiology. Founder status is distinguished from a current executive role.

Founding scientist of NMD Pharma. His Aarhus research focuses on skeletal-muscle channels and transporters and their roles in muscle function and fatigue. The published founder affiliation does not establish a current executive position.

NMD Pharma nonexecutive director since 2019. His biotech career includes Nido Biosciences CEO, Syros business leadership and Flagship Pioneering, after founding scientific and business-development work at Alexion. Holds degrees from Colby and Louisiana State University Medical Center.

NMD Pharma’s board chair since December 2022. A biopharma entrepreneur who founded Avenge Bio, Collegium Pharmaceutical and Precision Dermatology after beginning at Eli Lilly. He is a pharmacist with a Connecticut pharmacy degree. Board service does not establish a personal investment.

NMD Pharma’s Executive Assistant to the CEO since January 2023 and published ESG lead. Formerly developed institutional relations at British Patient Capital, with stakeholder-management and business-development experience. Holds a Surrey degree and investment-management qualifications.

NMD Pharma’s Vice President of Finance and IT since August 2024. Previous finance and digital-transformation work includes Danske Fragtmænd, EY and Novo Nordisk. Holds Aarhus finance, business and economics degrees.

NMD Pharma’s Senior Vice President, General Counsel and Head of People and Business Services since January 2024. Prior legal leadership includes LEO Pharma’s intellectual-property and R&D legal work and TDC. An attorney educated at Copenhagen with Seton Hall healthcare-compliance training.

NMD Pharma’s Senior Vice President of Corporate and Commercial Strategy since June 2023. Prior commercial leadership includes Catalyst Pharmaceuticals, Edge Therapeutics, Lundbeck US, Abbott and Eli Lilly. He holds Notre Dame and Northwestern Kellogg degrees.

NMD Pharma’s CMO since September 2025. A neurologist trained at Oviedo University, with development leadership at Santhera and Novartis spanning neurology and other therapeutic areas. Historical Jorge Quiroz CMO announcements do not override her current appointment.

Esther Crauser Delbourg is a publicly named current venture partner at GO Capital. Her official profile provides her affiliation and authentic portrait, while further career history and appointment dates remain undisclosed.